StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - Analyst
December 7, 2021 6:14 AM
On December 6th, after market closed, Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced positive top-line results from the pivotal, Phase 3 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Momentum Movers
Trader Talk
Next Articles
Acadia Pharma (ACAD) Stock Soars on Positive Rett Syndrome Results, Analysts Still Not Convinced
December 7, 2021 8:17 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman Sachs
December 7, 2021 6:39 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $26 at Mizuho Securities
December 7, 2021 6:30 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Citi
December 7, 2021 5:22 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
December 7, 2021 5:15 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $24 at Morgan Stanley
December 7, 2021 2:39 AM
Acadia Pharmaceuticals (ACAD) PT Raised to $39 at JMP Securities
December 7, 2021 2:02 AM
After-Hours Stock Movers 12/06: (ACAD) (MDB) (DWAC) Higher; (HQY) (OWL) (SI) Lower (more...)
December 6, 2021 5:27 PM
Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
December 6, 2021 4:07 PM
